FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+2.24%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.19B
AUM Growth
+$2.19B
(-9.2%)
Cap. Flow
-$90.6M
Cap. Flow
% of AUM
-4.14%
Top 10 Holdings %
Top 10 Hldgs %
70.17%
Holding
54
New
4
Increased
10
Reduced
8
Closed
7
Top Buys
| 1 |
MAZE
Maze Therapeutics, Inc. Common Stock
MAZE
|
$45.5M |
| 2 |
Avidity Biosciences
RNA
|
$15.5M |
| 3 |
Dyne Therapeutics
DYN
|
$15.1M |
| 4 |
Zai Lab
ZLAB
|
$12.6M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$10.1M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$63.1M |
| 2 |
Edgewise Therapeutics
EWTX
|
$33.9M |
| 3 |
AnaptysBio
ANAB
|
$20.8M |
| 4 |
Krystal Biotech
KRYS
|
$18M |
| 5 |
Pliant Therapeutics
PLRX
|
$14.8M |
Sector Composition
| 1 | Healthcare | 99.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$2.71B
| $330M | 15.08% | 16,116,418 +200,000 | +1% | +$4.09M |
|
|
2
Mirum Pharmaceuticals
MIRM
$3.71B
| $306M | 13.99% | 6,795,121 +224,729 | +3% | +$10.1M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $220M | 10.03% | 3,457,850 +73,900 | +2% | +$4.69M |
|
4
Arcutis Biotherapeutics
ARQT
$1.86B
| $137M | 6.28% | 8,785,284 | – | – |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $131M | 6% | 3,800,457 | – | – |
|
|
6
Krystal Biotech
KRYS
$4.27B
| $124M | 5.67% | 688,460 -100,000 | -13% | -$18M |
|
7
Disc Medicine
IRON
$2.07B
| $87.1M | 3.98% | 1,754,834 | – | – |
|
8
Tarsus Pharmaceuticals
TARS
$2.47B
| $71.8M | 3.28% | 1,397,527 -190,000 | -12% | -$9.76M |
|
9
Trevi Therapeutics
TRVI
$883M
| $64.5M | 2.95% | 10,259,409 -405,365 | -4% | -$2.55M |
|
10
Phathom Pharmaceuticals
PHAT
$864M
| $63.4M | 2.9% | 10,109,279 | – | – |
|
11
KalVista Pharmaceuticals
KALV
$678M
| $56.4M | 2.58% | 4,887,867 | – | – |
|
|
MAZE
12
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $45.5M | 2.08% | +4,129,001 | New | +$45.5M |
|
|
MBX
13
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $44.2M | 2.02% | 5,985,347 | – | – |
|
|
14
Rhythm Pharmaceuticals
RYTM
$6.85B
| $36M | 1.64% | 678,760 -1,191,048 | -64% | -$63.1M |
|
15
Soleno Therapeutics
SLNO
$3.6B
| $35.7M | 1.63% | 499,159 -200,000 | -29% | -$14.3M |
|
16
Revolution Medicines
RVMD
$7.1B
| $35.3M | 1.61% | 997,455 | – | – |
|
17
Savara
SVRA
$567M
| $31.8M | 1.45% | 11,462,301 +2,801,922 | +32% | +$7.76M |
|
18
Agios Pharmaceuticals
AGIO
$2.19B
| $31.3M | 1.43% | 1,069,854 +100 | +0% | +$2.93K |
|
19
Erasca
ERAS
$445M
| $30.9M | 1.41% | 22,575,851 +3,184,164 | +16% | +$4.36M |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $23.9M | 1.09% | 658,715 | – | – |
|
21
Ascendis Pharma
ASND
$11.8B
| $20.8M | 0.95% | 133,333 | – | – |
|
22
Vaxcyte
PCVX
$4B
| $20.4M | 0.93% | 539,405 | – | – |
|
23
Alkermes
ALKS
$4.78B
| $19.8M | 0.91% | 601,129 | – | – |
|
|
PVLA
24
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $19.3M | 0.88% | 690,012 +36,120 | +6% | +$1.01M |
|
25
CG Oncology
CGON
$2.04B
| $18.9M | 0.86% | 770,000 | – | – |
|